- Specialty Pharmacy List
- CAP Patient Enrollment Form
- Altera® Nebulizer System Instructions for Use
- Altera® Nebulizer System Instructions for Use en Español
CAYSTON provided results you can measure by improvement in FEV1 (L)
Mean percent change in FEV1 (L) was a prespecified secondary endpoint in AIR-CF1. Click here to review the study design.
CAYSTON demonstrated a significant improvement in FEV1 (L) lung function with a placebo-adjusted treatment effect of 10% (95% CI: 6%, 14%) on Day 28.
Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups continued but decreased to 6% (95% CI: 2%, 9%).
“When I'm on CAYSTON, I notice a positive difference in my coughing and see a boost in my lung function.”
–Kevin, CAYSTON patient, age 43